Annals of Oncology Advance Access originally published online on February 2, 2005
Annals of Oncology 2005 16(4):549-557; doi:10.1093/annonc/mdi116
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 European Society for Medical Oncology
Original articles |
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer
1 Royal Marsden Hospital, London and Surrey; 2 Southampton General Hospital, Southampton and Salisbury District Hospital, Salisbury; 3 Kent Oncology Centre, Maidstone; 4 Royal Bournemouth and Poole Hospitals, Dorset; 5 St George's Hospital, London; 6 Western General Hospital, Edinburgh; 7 Brighton and Sussex University Hospital, Brighton, UK
* Correspondence to: Professor D. Cunningham, Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK. Tel: +44-20-8661-3156; Fax: +44-20-8643-9414; Email: david.cunningham{at}icr.ac.uk
Background: We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of protracted venous infusion (PVI) 5-fluorouracil (5-FU) against the standard bolus monthly regimen of 5-FU/leucovorin (LV) given for 6 months as adjuvant treatment in colorectal cancer (CRC).
Patients and methods: Patients with curatively resected stage II and III CRC were randomly assigned to 5-FU/LV [5-FU 425 mg/m2 intravenously (i.v.) and LV 20 mg/m2 i.v. bolus days 1–5 every 28 days for 6 months] or to PVI 5-FU (300 mg/m2/day for 12 weeks).
Results: Between 1993 and 2003, 801 eligible patients were randomised to 5-FU/LV (n=404) or PVI 5-FU (n=397). With a median follow-up of 5.3 years, 231 relapses and 220 deaths have been observed. Five-year relapse-free survival (RFS) was 66.7% [95% confidence interval (CI) 61.6% to 71.3%] and 73.3% (95% CI 68.4% to 77.6%) with bolus 5-FU/LV and PVI 5-FU, respectively [hazard ratio (HR) 0.8; 95% CI 0.62–1.04; P=0.10]. Five-year overall survival (OS) was 71.5% (95% CI 66.4% to 75.9%) and 75.7% (95% CI 70.8% to 79.9%) with bolus 5-FU/LV and PVI 5-FU, respectively (HR 0.79; 95% CI 0.61–1.03; P=0.083). There was a significant survival advantage for patients starting adjuvant chemotherapy within 8 weeks (P=0.044). Significantly less diarrhoea, stomatitis, nausea and vomiting, alopecia, lethargy, and neutropenia (all with P <0.0001) were seen with PVI 5-FU.
Conclusions: There was no OS difference between the two arms, although PVI 5-FU was associated with a trend towards better RFS and OS compared with bolus 5-FU/LV, as well as significantly less toxicity. Based on our results, the probability of 12 weeks of PVI 5-FU being inferior to 6 months of bolus 5-FU/LV is extremely low (P <0.005), and therefore shorter duration of adjuvant treatment should be explored further.
Key words: adjuvant therapy, colorectal cancer, fluorouracil
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Berglund, B. Cedermark, and B. Glimelius Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III? Ann. Onc., February 1, 2008; 19(2): 400 - 402. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Yen-Revollo, R. M. Goldberg, and H. L. McLeod Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines? Clin. Cancer Res., January 1, 2008; 14(1): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Sanoff, H. Bleiberg, and R. M. Goldberg Managing Older Patients With Colorectal Cancer J. Clin. Oncol., May 10, 2007; 25(14): 1891 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer Adjuvant Treatment of Colorectal Cancer CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Benson III New Approaches to the Adjuvant Therapy of Colon Cancer Oncologist, October 1, 2006; 11(9): 973 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kerr KISS: the 2006 Annals of Oncology prizes Ann. Onc., September 1, 2006; 17(9): 1341 - 1342. [Full Text] [PDF]
|
|
|
|
|
|
I Chau and D Cunningham Adjuvant therapy in colon cancer--what, when and how? Ann. Onc., September 1, 2006; 17(9): 1347 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Smalley, J. K. Benedetti, S. K. Williamson, J. M. Robertson, N. C. Estes, T. Maher, B. Fisher, T. A. Rich, J. A. Martenson, J. W. Kugler, et al. Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144 J. Clin. Oncol., August 1, 2006; 24(22): 3542 - 3547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Neugut, M. Matasar, X. Wang, R. McBride, J. S. Jacobson, W.-Y. Tsai, V. R. Grann, and D. L. Hershman Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly J. Clin. Oncol., May 20, 2006; 24(15): 2368 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sobrero and S. Sciallero Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months? Ann. Onc., April 1, 2005; 16(4): 521 - 522. [Full Text] [PDF]
|
|